Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AstraZeneca PLC (AZN) vs Gilead Sciences, Inc. (GILD)

AstraZeneca PLC and Gilead Sciences, Inc. are both Drug Manufacturers General companies. AstraZeneca PLC is the larger, with a market value of $257.8B against $183.2B — 1.4× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; AstraZeneca PLC trades at 24.7×. AstraZeneca PLC grew revenue faster over the last twelve months: 8.61% against 5.52%. AstraZeneca PLC has the higher net margin (17.0% vs −10.6%) and the higher return on invested capital (11.7% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (4.27% vs 2.49%). Across the 22 metrics below, AstraZeneca PLC leads on 15 and Gilead Sciences, Inc. on 7.

Valuation

Metric AZN GILD Drug Manufacturers General median
P/E 24.72 n/m 24.72
P/S 4.21 6.16 3.35
P/B 5.13 15.97 5.00
Price to free cash flow 41.24 14.49 17.68
EV/EBITDA 13.91 804.10 13.91
EV/Sales 4.61 6.92 3.95
Earnings yield 4.05% (1.72%) 2.92%
Free cash flow yield 2.42% 6.90% 4.42%

Profitability

Metric AZN GILD Drug Manufacturers General median
Gross margin 81.88% 79.59% 72.77%
Operating margin 22.77% (8.20%) 18.90%
Net margin 17.02% (10.64%) 8.27%
Free cash flow margin 10.21% 42.50% 17.25%
Return on equity 21.95% (20.68%) 6.97%
Return on assets 9.15% (6.17%) 2.76%
Return on invested capital 11.67% (4.48%) 6.30%

Growth

Metric AZN GILD Drug Manufacturers General median
Revenue growth (TTM) 8.61% 5.52% 6.79%
EPS growth (last fiscal year) 45.43% 1,684.21% —
Revenue growth, 5-year CAGR 17.15% 3.58% 3.98%
Net income growth, 5-year CAGR 26.19% 133.35% 0.42%

Health

Metric AZN GILD Drug Manufacturers General median
Debt to equity 0.59 2.23 0.63
Current ratio 0.89 1.27 1.32
Net debt to EBITDA 1.13 1.35 1.15

Dividend

Metric AZN GILD Drug Manufacturers General median
Dividend yield 2.49% 4.27% 3.57%
Payout ratio 0.73 0.68 0.53

Size

Metric AZN GILD Drug Manufacturers General median
Market cap 257.79b 183.22b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack